Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Inclusion Criteria: * Current diagnosis of stable chronic kidney disease and eGFR, as assessed by the Modification of Diet in Renal Disease (MDRD) estimate: 1. Mild renal impairment: eGFR 60-89 mL/min/1.73m² 2. Moderate renal impairment: eGFR 30-59 mL/min/1.73m² 3. Severe renal impairment: eGFR \< 30 mL/min/1.73m² * Healthy control subjects with normal renal function will be matched (age ± 10 years; sex, race, BMI ± 15%) to their respective subject in the impaired renal function groups and have eGFR ≥90 mL/min/1.73m . Healthy control subjects should have no systemic chronic disease. * Males and Females age 18-75 * Body mass index (BMI) 25-40 kg/m² Exclusion Criteria: * Renal allograft recipients * History of renal cell carcinoma or any history of metastatic disease involving the kidney * End Stage Renal disease, requiring or not requiring dialysis * Subject requiring or anticipated requirement of dialysis within 3 months of study entry * Diagnosis of acute kidney injury/acute renal failure, or hospitalization for kidney related issue within 3 months of Screening * Any renal disease or related condition actively being treated other than chronic kidney disease * Any acute disease or condition being treated by medical therapy (prescription or over the counter) known to possibly impact renal function within 2 weeks of Screening * History of treatment for a chronic condition with a medication that is known to have nephrotoxic potential, and after treatment, renal function/status has not been fully evaluated * Uncontrolled hypertension * Uncontrolled diabetes